FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
For Immediate Release: March 26, 2026 The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). Kresladi is indicated for the …